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A B S T R A C T
Background: Both young and old leaves of Vernonia amygdalina (VA) are traditionally used to treat inflammation,
pain and fever. However, the efficacy of young and old leaves for treating these ailments have not been com-
pared till date.
Aim: To ascertain the effect of young and old leaves of VA in managing inflammation, pain and fever.
Methods: Both quantitative and qualitative phytochemical screening of ethanol extracts of young (EthYL) and
old (EthOL) leaves of VA were performed. The anti-inflammatory activity of orally administered EthYL and
EthOL (50–200mg/kg) and Diclofenac (10mg/kg) were evaluated in carrageenan-induced inflammation model
in rats. Antipyretic activity of EthYL, EthOL and Aspirin (25mg/kg) were assessed in the Baker’s yeast-induced
pyrexia model. Anti-allodynic effect of both extracts were evaluated by inserting inflamed paws of rats in cold
water. Antinociceptive property of the extracts were assessed using tail withdrawal and formalin-induced no-
ciception test. Histopathological examination of the paws was performed, in addition to formalin test to un-
derstand the possible mechanism of action of the extracts. Negative control rats received 2ml/kg normal saline
in all tests.
Results: The amount of flavonoids, alkaloids, tannins, and phenolics were significantly (p < 0.05) higher in
EthOL than EthYL, while saponins were significantly higher (p < 0.05) in EthYL than EthOL. The antioxidant
ability and total antioxidant capacity were significantly (p < 0.05) higher in EthYL than EthOL. However, this
was significantly (p < 0.05) lower than the anti-oxidant activity of Ascorbic acid. A dose-dependent increase in
anti-inflammatory, antipyretic and antinociceptive properties were observed in both EthYL and EthOL, similar to
the standard drugs. Mast cell degranulation accompanied by vasodilatation and high leukocytosis were observed
in the negative control, but were markedly low in extract treated groups. Both extracts mediated their analgesic
effect through opioidergic and nitric oxide pathways with EthYL additionally implicating the muscarinic cho-
linergic system.
Conclusion: Although both EthYL and EthOL alleviate inflammation, pyrexia and nociception, EthYL of VA was
found to be more potent than EthOL.
1. Introduction
Inflammation is an immunological response to infection, damaged
cells, irritants, mechanical and chemical injuries, in an attempt to
eliminate injurious stimuli and initiate a healing process of the
damaged tissue [1,2]. Pain, swelling (edema), heat and redness are the
four cardinal signs associated with acute inflammation [3,4]. An in-
crease in vascular permeability, as seen in acute inflammation, results
in the exudation of plasma rich fluid, accompanied by the inflow of
proteins such as albumin into the damaged tissue area. The result is an
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edematous lesion [3,5]. Pain is associated with many ailments and is
usually the main factor that prompts patients to seek medical attention
[6]. Pain occurs as a result of nociceptive, inflammatory or neuropathic
conditions [7], while pyrexia or fever manifests as a secondary impact
of infection or tissue damage as seen in inflammation, graft rejection,
tumour malignancy or other diseased states [5,8]. The infected or da-
maged tissue initiates the enhanced synthesis of pro-inflammatory
mediators or cytokines such as interleukin -1β and tumor necrosis
factor (TNF)-α, which increases the production of prostaglandin E2
(PGE2) near the area of preoptic hypothalamus. PGE2 then sends sig-
nals to the hypothalamus which elevates the body temperature beyond
the set point of 37.5–38.3 °C in the anus or rectum, 37.7 °C in the mouth
and 37.2 °C under the arm or axillar [5,9,10]. Most antipyretic agents
exert their temperature-reducing effect by inhibiting PGE2 biosynthesis
[11].
Although there are many proven and effective drugs on the market
for the management of inflammatory conditions, they are accompanied
with varying toxic and life-threatening side effects [12,13]. It is,
therefore, prudent that much more viable treatments with milder toxic
effects, reliable, efficacious and cost-effective herbal-based products
made available to the populace due to their continuing wide usage; be
investigated, and possibly used as alternative means of such manage-
ment.
The leaves of Vernonia amygdalina (VA) have found relevance in
traditional folk medicine for many years as antipyretic, antimalarial,
antimicrobial, antidiabetic, anthelminthic, an immune system booster,
energizer, and as a pain reliever [14–18]. In recent years, interest in the
constituents of VA as potent anti-inflammatory and antimalarial agents
have attracted both research [19–21] and clinical [22] attention.
Whereas some therapeutic abilities of the mixture of young and old
leaves of VA have been given scientific credence [19,21], there is no
literature backing the anti-inflammatory efficacy of these leaves when
used singly or separately. We have previously demonstrated that the
young leaves of VA possess higher antioxidant and antidiabetic poten-
tials as compared to the old leaves [15].
This study thus seeks to ascertain the pharmacotherapeutic useful-
ness of young and old leaves of VA in the management of pain, fever
and edema caused by acute inflammation, and also report for the first
time, the quantitative analysis of the young and old leaves of VA.
2. Materials and method
2.1. Drugs and chemicals
Carrageenan and 2,2-diphenyl-1-picryl hydrazyl (DPPH) radical
(Sigma-Aldrich Inc., St. Louis, MO, USA); baker’s yeast (Saf-instant, S.I.
Lesaffre, France); Diclofenac sodium and Aspirin (Troge Medical
GmbH, Hamburg, Germany); formalin, NG-L-nitro-arginine methyl ester
(L-NAME) (Sigma-Aldrich Inc., St. Louis, MO, USA); glibenclamide
(Daonil®, Sanofi-Aventis, Guildford, UK); yohimbine hydrochloride
(Procomil®, Walter Ritter GmbH+Co. KG, Germany); atropine sul-
phate, naloxone hydrochloride, morphine sulphate (Duopharma (M)
Sdn Bhd, Malasia) and nifedipine (Denk Pharma, Germany). All drugs
and reagents were of high standard grade and freshly prepared before
used.
2.2. Collection and preparation of ethanolic leaf extracts
V. amygdalina leaves (bitter leaf) were collected from the Botanical
Garden of the School of Biological Sciences, University of Cape Coast
(UCC), Cape Coast, Central Region of Ghana, and were subsequently
identified by a botanist at UCC. Samples were deposited in the School’s
herbarium, with the accession number CE 001. The leaves were har-
vested from the same plants and then grouped into young leaves (YL)
and old leaves (OL) following the criteria described previously [15,23].
Furthermore, the average number of days by which the YL develops
into OL was evaluated. Here, the lower limit by length of YL (5.10 cm)
was chosen, and petioles of young vegetative leaves with this length
were identified and marked with an indelible marker. These YL of VA
were measured every day until they got exactly to or just above the
upper limit by length (15.50 cm) of the old vegetative leaves. The
average number of days was estimated to be 21 days (range: 19–23
days).
For the extract preparation, briefly, VA leaves (both YL and OL)
were air-dried separately for two weeks, pulverized and stored in air-
tight plastic containers. Powdered YL and OL were macerated in cold
ethanol for 72 h, separately, and the extracts were collected. This pro-
cess was repeated thrice for exhaustive extraction and the extracts were
concentrated to dryness using a rotary evaporator. The extract con-
centrates were labelled and percentage yield was calculated in %w/w
and stored at 4 °C in sealed containers until further use.
The yield was 19% w/w for ethanolic leaf extract of YL (EthYL) and
22% w/w for ethanolic leaf extract of OL (EthOL). Concentrations (50,
100, and 200mg/ml) of both extracts were prepared from the stored
extracts for oral administration.
2.3. Phytochemical screening
The chemical classes of the bioactive compounds present in EthYL
and EthOL were investigated using standard phytochemical screening
procedures, according to the methods described previously [24,25].
Quantitative analysis of the phytochemicals screened was done using
standard procedures explained earlier [26–30].
2.4. In vitro antioxidant activity
The antioxidant activity of EthYL and EthOL extracts was assessed
by DPPH free radical assay [31]. The reaction mixture containing 1ml
of varying concentration of EthYL or EthOL was mixed with 3ml of
methanol and 0.5 ml of 1mM DPPH. The mixture was shaken vigor-
ously and left to stand in the dark. The decrease in the DPPH-radical
was measured at 517 nm by UV–vis spectrophotometer (Evolution™
60S, Thermo Scientific, Germany). Ascorbic acid (vitamin C) was used
as a standard antioxidant. Concentrations of 0.05, 0.1, 0.5, 1.0, 2.0 and
5.0 mg/ml EthYL and EthOL were prepared in methanol. Ascorbic acid
(vitamin C) was used as a standard antioxidant at the concentrations
0.05, 0.1, 0.2, 0.5, and 0.75mg/ml. The antioxidant activity of EthYL
and EthOL was calculated using the formula:
= ×inhibition Ab Aa
Ab
% 100
where ‘Ab’ = absorption of the blank sample and ‘Aa’ is the absorption
of the extract.
2.5. Experimental animals
Sprague-Dawley rats weighing 250 ± 50 g and ICR mice weighing
21–38 g, of both sexes, were randomly selected from the animal house
of the Department of Biomedical Sciences, University of Cape Coast
(UCC). The animals were kept in stainless steel cages
(34.5×47.6×18.5 cm) with soft wood shavings as bedding material,
under ambient conditions of temperature (23 ± 2 °C), relative hu-
midity (60–70%), 12 h light/dark cycle and water and rat/mice chow
were available ad libitum. However, preceding drug administration,
animals were fasted overnight but were still allowed free access to clean
water.
All animals used were handled in accordance with the National
Institute of Health Guidelines for Care and Use of Laboratory Animals
(NIH, Department of Health and Human Services publication no. 85-23,
1985, revised 1996). All protocols used were approved by the
Departmental Ethics Committee.
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2.6. Carrageenan-induced paw edema in rat
Anti-inflammatory evaluation was done using the carrageenan-in-
duced paw edema method as described previously [32]. Edema was
induced by injecting 100 μl of freshly prepared 2% carrageenan into the
subplantar surface of the left hind paw of 8 groups rats (n=5) whereas
the sham control (9th) group rats received intraplantar injection of
vehicle (100 μl of normal saline). Prior to the induction of inflamma-
tion, baseline recordings were taken by measuring the diameter of the
non-inflamed left hind paw of the rats, using a digital caliper. The
diameter of the inflamed left hind foot was measured one hour later to
assess the effect of carrageenan on the size of the foot. The rats in the
various groups were then dosed with the extracts, EthOL and EthYL, at
50, 100, and 200mg/kg, p.o, diclofenac (10mg/kg, p.o.) or normal
saline (10ml/kg, p.o.). One hour after treatments, the diameter of the
left hind paw of the rats were measured at every one hour for 4 h, to
ascertain the effect of VA on the inflamed left paw. Raw scores of the
foot edema were individually normalized as percentage of change in
their paw diameter at time 0 and then averaged for each treatment
group as follows:
= ×change in paw edemaPaw thickness at time t Paw thickness at time
Paw thickness at time
%
0
0
100
This was used to plot a time course curve for the 5 - h period. Total
edema response for each treatment was then calculated as area under
the time course curves. The effect of the drugs was evaluated using
percentage inhibition of edema calculated using the formula below:
= ×inhibition AUC AUC
AUC
% ( ) 100control treatment
control
2.7. Carrageenan-induced cold allodynia
The test was carried out as described earlier [33]. The temperature
of cold water was set at 4 °C ± 0.5 °C and allowed to stabilize for
5min. Each hind paw of the animals was then placed into the cold
water and the time (in seconds) taken for the first brisk lift paw to occur
was recorded (baseline). The time to the brisk response was interpreted
as the latency for cold pain withdrawal.
A maximum cut-off time of 10 s was used to prevent tissue damage
at the lower temperatures. An amount of 100 μl of 2% carrageenan was
then injected into the left hind paw of the rats to induce inflammation.
2 h post carrageenan injection, the rats were put into eight groups
(n=5), and were treated orally as follows: Group A (positive control,
Diclofenac, 10mg/kg), Group B, (the negative control, normal saline,
2 ml/kg) Groups C, D and E were treated orally with EthYL at doses of
50, 100, and 200mg/kg, respectively, whereas Groups F, G and H were
received EthOL at doses of 50, 100, and 200mg/kg. The sham control
(SC) group rats received intraplantar injection of vehicle (100 μl of
normal saline) and were subsequently treated with normal saline, 2 ml/
kg. 1 h after the various drug treatments, the test was carried out again
at 1 h intervals for 4 h to ascertain the effect of VA on induced pain. The
latency to paw withdrawal of the rats to allodynia was used to calculate
the percentage maximum possible effect (MPE) of the extracts, at a cut-
off latency of 10 s.
=
×
MPE Total Treatment Response Time Total Baseline Response Time
Cut off Latency Time Total Baseline Response Time
%
100
This was used to plot a time course curve for the 4 - h period. Total
anti-nociceptive effect for each treatment was then calculated as area
under the time course curves.
2.8. Tail immersion test
The test was carried out as described earlier [20]. This experiment
was done using hot water maintained at 55 ± 0.5 °C in a bath. Briefly,
rats were put into eight groups, A–H (n = 5). Group A was treated
orally with 10mg/kg diclofenac, Group B, was treated orally with
normal saline (2ml/kg), Groups C, D and E were treated orally with
EthYL extracts at doses of 50, 100, and 200mg/kg respectively,
whereas Groups F, G and H were treated orally with EthOL extracts at
doses of 50, 100, and 200mg/kg. The 5 cm length from the tip of the
tail of the rats was immersed into the hot water maintained at
55 ± 0.5 °C with the rats held vertically above the water bath. The cut-
off time for the test was set to 10 s after which the subjects were
withdrawn to prevent tissue damage. The time (in seconds) from the
dipping of tail into the hot water and rapid flick/withdrawal from hot
water was recorded. The percentage maximum possible effect (MPE) of
the extract was calculated using a similar formula as indicated above
under cold allodynia.
2.9. Formalin test
This test was performed as described previously [34,35]. Eight
groups (n= 5) of ICR mice were used for the test. Each mouse was
placed in one of twenty Perspex chambers (15×15×15 cm) for one
hour prior to formalin injection for them to acclimatize to the new
environment. Each group of mice received either vehicle (10ml/kg
distilled water, p.o.), EthOL (50, 100 and 200mg/kg, p.o.), EthYL (50,
100 and 200mg/kg, p.o.) or morphine (3mg/kg, i.p.) 60min (p.o.) or
30min (i.p.) before intraplantar injection of 5% v/v formalin (10 μl)
into their right hind paws. Mice were instantly transferred into the
transparent testing chamber. They were then captured with the aid of a
camcorder for 60min A nociceptive score for every 5min time bloc was
obtained by measuring the duration and frequency of licking/biting of
injected paws and the mean nociceptive score for each time bloc per
5min determined as the product of the duration and frequency of
licking/biting. The results obtained were considered as early/neuro-
genic phase (0–10min) and late/inflammatory phase (10–60min) from
which time-course curves were plotted and the areas under the curve
for each phase and each treatment determined and plotted. The per-
centage inhibitions of the treatment groups were obtained using a si-
milar formula as described under paw edema. The results were also
used to plot a dose-response curve from which the ED50 were de-
termined. Excised tissues were also taken from the right hind paws from
each group for histological analysis.
2.10. Yeast-induced pyrexia model in rats
Yeast-induced pyrexia model [36] was used to assess the antipyretic
potential of EthYL and EthOL in Sprague-Dawley rats. Nine groups of
rats (n= 5) labeled A–I were used for the study. Group A, the sham
Table 1
Total phenolic content, flavonoids, tannins, total antioxidant capacity, saponins
and percentage alkaloids of ethanolic extract of young and old leaf parts of V.
amygdalina.
Phytochemical EthYL EthOL p-value
Total phenolics 0.165 ± 0.002 0.212 ± 0.011 0.0021***
Flavonoids 0.377 ± 0.008 0.663 ± 0.061 <0.0001****
Tannins 1.555 ± 0.009 1.925 ± 0.187 <0.000017****
TAC 0.245 ± 0.031 0.150 ± 0.012 <0.0001****
Saponins 34.480 ± 0.667 29.390 ± 2.514 <0.00001****
Alkaloids 2.672 ± 0.018 5.332 ± 0.018 <0.0001****
Data is shown as mean ± SEM; (n=2). Significance in difference between YL
and OL extract of VA. P < 0.05 (unpaired t-test with Welch’s correction). TAC:
Total antioxidant capacity.
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control, were treated orally with 2ml/kg normal saline. Group B, the
negative control was treated orally with 2ml/kg normal saline whereas
Group C, the positive control, was treated with 25mg/kg aspirin.
Groups D, E, and F were treated orally with EthYL at doses of 50, 100,
and 200mg/kg respectively, whereas Groups G, H, and I were treated
orally with EthOL at doses of 50, 100, and 200mg/kg respectively.
Before pyrexia was induced, baseline rectal temperatures of the rats
were taken using a digital thermometer. Pyrexia was induced by mul-
tiple intraperitoneal injections of baker’s yeast suspension (0.135 g/kg),
after which the animals were fasted for 18 h. Rectal temperatures were
then taken at the 18th and 19th hours after which EthYL, EthOL,
normal saline and aspirin were administered to rats with a 0.5 °C rise in
temperatures. Rectal temperatures were again taken at the first, second
and third hours post-treatment, and then the next morning. Raw scores
for basal and changes in rectal temperatures were individually nor-
malized as percentage of change from their values at time 0, and then
averaged for each treatment group. Time-course curves were then
plotted from which the total change in rectal temperature for each
treatment was calculated in arbitrary unit as the area under the curve
(AUC). The percentage inhibition for each treatment group was calcu-
lated as described under Section 2.6.
2.11. Mechanism of action of extracts
The mechanisms mediating the analgesic effect of EthOL and EthYL
were assessed using opioidergic, ATP sensitive K+ channels, nitric
oxide, muscarinic, adrenergic and voltage-gated calcium channel
pathways in the formalin test as described previously [37,38]. Selection
of doses for the test was based on preliminary studies in our lab [39,40].
The involvement of the above pathways was assessed by pre-
treating mice (n= 5) with naloxone (a non-selective opioid receptor
antagonist, 2 mg/kg, i.p.), atropine, (a non-selective muscarinic
Fig. 1. Effect of EthYL and EthOL (50, 100, and 200mg/kg) treatments on yeast-induced pyrexia in rats. “a and c”, show the percentage change in temperature over
time in EthYL and EthOL treated groups, respectively. “b and d” represent the total percentage pyrexia calculated as AUC in yeast-induced pyrexia in rats. Data is
plotted as mean ± SEM. *P<0.05; **P<0.01; and ***P<0.001; comparing drug treatments to the negative control (two-way ANOVA followed by Dunnet’s post-
hoc test). †P<0.05; ††P<0.01; and †††P<0.001; comparing drug treatments to the negative control (one-way ANOVA followed by Newman-Keuls post-hoc test).
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antagonist, 5 mg/kg, i.p.), nifedipine (10mg/kg, p.o., L-type voltage-
gated calcium channel blocker), glibenclamide (an ATP-sensitive po-
tassium channel inhibitor, 8 mg/kg, p.o.), L-NAME (10mg/kg, i.p., a
nitric oxide synthase inhibitor), yohimbine, (an alpha-2 receptor an-
tagonist, 3 mg/kg, p.o.) or vehicle. After 15min (i.p) or 30min (p.o.),
mice received EthOL (200mg/kg, p.o.), EthYL (200mg/kg, p.o.), mor-
phine (3mg/kg, i.p.) or vehicle (10mL/kg, p.o.). After 1 h (p.o.) or
30min (i.p.), the nociceptive responses to formalin were recorded, with
the aid of a camcorder for 60min., and analysed similar to formalin test
results.
2.12. Histological analyses
Mice that received formalin injection subcutaneously into their right
hind paw were euthanized after 2 h (after phase 2). Excised tissues from
the right hind paws were fixed in 10% phosphate buffered formalin.
They were subsequently dehydrated, cleared and embedded in paraffin
wax to form tissue blocks. Serial sections were taken using a rotary
microtome and stained using routine haematoxylin and eosin (H&E)
and toluidine blue. H&E staining were employed for analysing leuco-
cytic cell infiltrates, vasodilation and congestion; while the special stain
(Toluidine blue) was used for evaluating mast cell degranulation
dynamics.
2.13. Statistical analyses
GraphPad Prism Version 7 was used for data analyses. Data are
presented as mean ± standard error of mean (mean ± SEM).
Differences in data for sham, treatments, and the negative control (NC)
were analyzed using ANOVA. Further, comparisons were performed
using Dunnett’s post-hoc and Newman Keuls’ post hoc tests. P ≤ 0.05
was considered statistically significant.
3. Results
3.1. Phytochemical screening and antioxidant activity
The results from the phytochemical screening of both EthYL and
EthOL is shown in S Table1. Both extracts were positive for alkaloids,
tannins, saponins, cardiac glycosides, terpenes and steroids. EthYL ex-
tracts were negative for flavonoids, while EthOL were positive for fla-
vonoids. Quantitative analysis revealed the presence of significantly
higher (p < 0.05 – 0.001) quantities of total phenolics, flavonoids,
tannins and alkaloids in EthOL than in EthYL. Phytochemical assay is a
Fig. 2. Effects of EthYL and EthOL (50, 100, and 200mg/kg) treatments on carrageenan-induced paw edema in rats. “a and c” show the percentage change in
edematous paw size in EthYL and EthOL treated groups, respectively, over time. “b and d” represent the total percentage edema calculated as AUC in carrageenan-
induced edema. Data is plotted as mean + SEM. *P<0.05; **P<0.01; and ***P<0.001; comparing drug treatments to the negative control (two-way ANOVA
followed by Dunnet’s post-hoc test). †P<0.05; ††P<0.01; and †††P<0.001; comparing drug treatments to the negative control (one-way ANOVA followed by
Newman-Keuls post-hoc test).
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less sensitive assay and the presence of low quantities of flavonoids
might have been insufficient to trigger the chemical reaction. The total
antioxidant capacity (TAC) and saponins were significantly higher in
EthYL than in EthOL (p < 0.01) (Table 1).
3.2. Effect of EthYL and EthOL on yeast-induced pyrexia
Pyrexia was observed 21 h post-induction with yeast in the rats
(Sprague-Dawley), with a mean rectal temperature of 36.57+ 0.17 °C
which increased to 38.17+ 0.63 °C. Treatment with 200mg/kg EthYL
and EthOL extracts induced a significant (p < 0.05) inhibition of
pyrexia by 78.54% and 31.78%, respectively; while Aspirin, the re-
ference drug, inhibited pyrexia by 71.26%. No significant change in
rectal temperature was observed in the Normal control group (Fig. 1). A
dose-dependent antipyretic activity was exhibited by both EthYL and
EthOL extracts. However, EthYL extracts were found to have better
antipyretic activity than EthOL.
3.3. Effect of EthYL and EthOL on edema
Edema was observed two hours post-induction by carrageenan (2%)
in the left hind paw. A mean of 73.83% increase in paw size was ob-
served in the negative control group as shown on Fig. 2a and c.
Treatment with Diclofenac (10mg/kg; reference anti-inflammatory
drug) reduced the total edematous paw size significantly by 76.52%
(p < 0.01). Treatment with EthYL extracts (50, 100, and 200mg/kg)
significantly (p < 0.05) exhibited a dose-dependent reduction in
edema (59.61%, 67.52% and 86.31%) 2 h post-treatment. Similarly,
treatment with EthOL (50, 100 and 200mg/kg) also exhibited a sig-
nificant (p < 0.05) dose-dependent reduction in edema (56.11,
63.37% and 67.41%, respectively) 2 h post-treatment (Fig. 2c and d).
3.4. Effect of EthYL and EthOL on pain
3.4.1. Carrageenan induced cold allodynia
A dose-dependent decrease in cold allodynia was observed with
both EthYL and EthOL extracts, after 2 h of treatment. Both 100 and
200mg/kg EthYL and EthOL extracts significantly (P≤ 0.05) inhibited
the carrageenan induced cold allodynia in the rats, similar to Diclofenac
(P < 0.05), the reference analgesic (Fig. 3 and S Table 2). Again, the
EthYL extracts showed better inhibition of the cold allodynia than the
EthOL extracts.
3.4.2. Tail immersion test
The analgesic activity of EthYL and EthOL measured by tail-im-
mersion test is shown in Table 3. Treatment with both EthYL (50, 100
and 200mg/kg) and EthOL (200mg/kg) increased the tail withdrawal
latency significantly (P ≤ 0.05) (Fig. 4 and S Table 3). Diclofenac was
used as a standard for this test.
3.4.3. Formalin test
Pain reaction in formalin induced pain model is usually observed as
a biphasic reaction – first phase (neurogenic phase) characterized by an
immediate, intense pain response (0–10min) and the second phase
Fig. 3. Effects of EthYL and EthOL (50, 100, and 200mg/kg) treatments on carrageenan induced cold allodynia. “a and c” represent the percentage change in
response time to cold allodynia and “b and d” the total change in response time to cold allodynia calculated as AUC.
*P<0.05; **P<0.01; and ***P<0.001; comparing drug treatments to the negative control (two-way ANOVA followed by Dunnet’s post-hoc test). †P<0.05;
††P<0.01; and †††P<0.001; comparing drug treatments to the negative control (one-way ANOVA followed by Newman-Keuls post-hoc test).
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(inflammatory) is characterized by delayed pain due to the release of
inflammatory mediators (10–60min). A dose-dependent decrease in the
licking time was observed in morphine, EthYL and EthOL treated
groups. Oral administration of both EthOL and EthYL one hour prior to
formalin injection produced a significant antinociceptive effect (all
P < 0.05). At 200 mg/kg, both EthOL and EthYL produced a max-
imum inhibition of 65.1± 3.65% and 76.97±3.25%, respectively, in
the phase I; and 77.91± 3.95% and 92.57±0.86% in the in-
flammatory phase. Morphine (3 mg/kg, i.p.) was used as a reference
drug and significantly (P<0.001) reduced both phases of pain re-
sponse with a maximum inhibition of 86.62± 3.35% and
95.91± 2.67%, respectively (Fig. 5).
Dose-response curves plotted using non-linear regression estimated
the ED50 values of EthOL and EthYL (Fig. 6) as 72.67 ± 1.22mg/kg
and 48.19 ± 1.17mg/kg respectively for phase 1. Similarly, phase 2
ED50 values calculated for EthOL and EthYL were 74.12 ± 1.11mg/kg
and 59.79 ± 1.08mg/kg respectively. EthYL was 1.5 times more po-
tent than EthOL in the first phase and 1.23 times more potent than
EthOL in the second phase.
3.5. Mechanism of analgesic effect
Figs. 7–10 show the effect of pre-treatment of mice with naloxone
(2mg/kg, i.p.), atropine (5mg/kg, i.p.), nifedipine (10mg/kg, p.o.),
glibenclamide (8mg/kg, p.o.), L-NAME (10mg/kg, i.p.) and yohimbine
(3mg/kg, p.o.) on the anti-nociceptive activities of EthOL, EthYL and
morphine. Both phase 1 and phase 2 anti-nociceptive effects of EthYL,
EthOL, (200mg/kg, p.o.) and morphine were reversed by pre-treatment
of mice with naloxone and L-NAME. In addition, phase 2 of atropine
pre-treatment reversed the antinociceptive activity of EthYL but not
EthOL. Pre-treatment with all the antagonists reversed the anti-
nociceptive activity of morphine in both phases of the formalin test
(Fig. 10).
3.6. Histopathological evaluation
Fig. 11A–I reveals the histoarchitecture of the dermis from the right
hind paw of the mice at a total magnification of ×100, using the H&E
stain. Section from the normal control group (Fig. 11A), has irregularly
arranged loose upper and dense lower dermal connective tissue layer
just below the epidermis. Tissue fibres looks compact with no extra-
vasation of leucocytes. In contrast, the negative control group
(Fig. 11B) shows severe leucocytic infiltration accompanied with dila-
tion of blood vessels. Leucocytosis are mostly evident in perivenular
areas. Some vessels show congestion accompanied with leucocytic pa-
vementing and margination on endothelial walls. Edema is present, but
masked by erythrocytic infiltrate in congested areas. In the positive
control group (Fig. 11C), sections show mild leucocytic infiltrate, with
noticeable signs of edema. The reference drug (Morphine) seems to
counteract the leucocytic transmigratory pathway, hence reducing the
inflammatory cell infiltrate.
For the lower dose of the extracts, sections from the 50mg/kg EthYL
(Fig. 11D) reveals areas of focal leucocytic infiltrates devoid of con-
gestion, with the 50mg/kg EthOL (Fig. 11E), showing diffused leuco-
cytic infiltrates accompanied with congestion and mild edema. The
lesions in Fig. 11E is comparably lower than the ones found in the
Fig. 4. Effect of EthYL (50, 100, and 200mg/kg) and EthOL (50, 100, and 200mg/kg) treatments, on time course curves of latency to tail withdrawal from hot water
(a and c) and (b and d) the total anti-nociceptive score calculated as the AUC. Values plotted are mean ± SEM. *P<0.05; **P<0.01; and ***P<0.001; comparing
drug treatments to the negative control (two-way ANOVA followed by Dunnet’s post-hoc test). †P<0.05; ††P<0.01; and †††P<0.001; comparing drug treatments
to the negative control (one-way ANOVA followed by Newman-Keuls post-hoc test).
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Fig. 11B (negative control group). Furthermore, sections from the mice
dosed with 100mg/kg EthYL (Fig. 11F), shows mild edema with tissue
architecture comparable to the normal control group. The 100mg/kg
EthOL (Fig. 11H) on the other hand, shows mild leucocytosis accom-
panied by focal congestion in vessels. For the high dose (200mg/kg) of
both extracts, sections from the EthYL group shows tissue architecture
comparable to the normal control group; thus, indicative of high anti-
inflammatory activity. However, the EthOL did not show similar anti-
inflammatory effect; it reveals focal areas of mild leucocytosis accom-
panied with edema.
Fig. 5. Effect of EthOL (50, 100 and 200mg/kg, p.o.), EthYL (50, 100 and 200mg/kg, p.o.), and morphine (3mg/kg, i.p.) on the time-course curves (a and c) and the
total nociceptive score (calculated as AUCs) (b and d) in formalin-induced nociceptive test in mice. Each data represents the mean ± S.E.M (n= 5). The symbol †
indicate significance levels compared to respective controls: †††P < 0.001, ††P < 0.01 and †P < 0.05 (one - way ANOVA followed by Newman Keuls’ post hoc).
Fig. 6. Dose-response curves of EthOL (50, 100 and 200mg/kg, p.o.) and EthYL (50, 100 and 200mg/kg, p.o.) in phase 1(a) and phase 2(b) of formalin-induced
nociception test in mice.
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For histological evaluation of dermal mast cells (MC) in association
with leucocytic infiltration (Fig. 12A–I), the routine H&E stain was
employed once more, and analysed at a total magnification of ×400.
These connective tissue MCs in the dermal areas were mostly found
around the perivascular or venular areas. These cells, which are re-
sidential mononuclear immune cells could be differentiated from ex-
travasated leucocytes by their large and highly conspicuous eosino-
philic cytoplasm (Fig. 12). MCs could be seen in the intact or non-
activated state in the normal control group (Fig. 12A), with no asso-
ciation with peripheral leucocytic infiltrates. The negative control
group (Fig. 12B) on the other hand, shows degranulation of MCs, as-
sociated with high infiltration of polymorphonuclear leucocytes
(PMNL); mostly multilobed neutrophils (predominant cells in acute
inflammation). Signs of high inflammatory exudate (edema) are also
evident. The positive control group (Fig. 12C) had few moderately
degranulated MCs and also non-activated MCs, accompanied with mild
leucocytic infiltrate. Sections from 50mg/kg EthYL (Fig. 12D) group
had few PMNL as compared with Fig. 12C. It also shows very few intact
and moderately degranulated MCs, with signs of exudation (edema).
The 50mg/kg EthOL group (Fig. 12E), reveals sections that show
Fig. 7. Effect of pre-treatment of mice with (a) naloxone (2mg/kg i.p.), (b) atropine (5mg/kg, i.p.), (c) nifedipine (10mg/kg, p.o.), (d) glibenclamide (8mg/kg, p.o.)
(e) L- NAME (10mg/kg, i.p) and (f) yohimbine (3mg/kg, p.o.), on the anti-nociceptive profile of EthYL, (200mg/kg, p.o.) in phase 1 and phase 2 of formalin-induced
nociception. Each column represents the mean of 5 animals and the error bars indicate S.E.M.
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moderate PMNL infiltrate with few moderately degranulated MCs, with
signs of edema. Fig. 12F (100mg/kg EthYL) demonstrates the presence
of activated MCs, with very few patchy PMNL infiltrate, devoid of
edema. Similarly, the 100mg/kg EthOL (Fig. 12G), shows mild de-
granulated MCs accompanied by moderate leucocytic infiltrate, with no
sign of edema. For the high dose (200mg/kg) of the extracts, section
from the EthYL group (Fig. 12H), shows intact MCs with very few
PMNL. Tissue consistency in this group is likened to that of the normal
control group. Sections from its counterpart (EthOL) as shown in
Fig. 12I, demonstrates the presence of both intact and mildly de-
granulated MCs, with moderate infiltration of PMNL.
Based on the degree of degranulation, using toluidine blue stain,
four main types of MCs were identified during the inflammatory con-
dition. These are; (a) Intact or non-activated MCs: Deep blue ortho-
chromatic staining with conserved cell membrane without extrusion of
granules, and having pale metachromatic nuclei, (b) Activated MCs:
Amorphous shape with no sign of degranulation, but absence of visible
pale metachromatic nuclei, (c) Moderate/mild degranulation: MCs from
which some granules have been released, but outline of cell membrane
retained (d) Severe degranulation: Cytoplasmic granules of MCs is
widely spread, accompanied by total distortion of the outline of its cell
membrane. These have been reported previously [41,42]; excluding ‘b’
(identified by this current research).
Using the criteria described above, Fig. 13A (normal control group)
shows sections populated with intact MCs. The negative control
(Fig. 13B) reveals MCs with severe degranulation. The positive control
(Fig. 13C) on the other hand, demonstrates population of activated and
mildly degranulated MCs. Thus, good MC stabilizing activity of the
reference drug (Morphine).
Sections from both low dose (50mg/kg) groups, show mild to
Fig. 8. Effect of pre-treatment of mice with (a) naloxone (2mg/kg i.p.), (b) atropine (5mg/kg, i.p.), (c) nifedipine (10mg/kg, p.o.), (d) glibenclamide (8mg/kg, p.o.)
(e) L- NAME (10mg/kg, i.p) and (f) yohimbine (3mg/kg, p.o.), on the anti-nociceptive profile of EthOL, (200mg/kg, p.o.) in phase 1 and phase 2 of formalin-induced
nociception. Each column represents the mean of 5 animals and the error bars indicate S.E.M.
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severe degranulation of the MCs, with the 50mg/kg EthYL (Fig. 13D)
showing mild degranulation, and its counterpart, EthOL (Fig. 13E),
exhibiting moderate to severe degranulation of the MCs. Histological
section from the 100mg/kg EthYL group (Fig. 13F) shows mild and
activated MCs, with the old counterpart (Fig. 13G) showing pre-
dominantly MCs with mild degranulation. Thus, both 50 and 100mg/
kg EthYL show higher MC stabilizing effect than their corresponding
EthOL (50 and 100mg/kg) groups respectively. Fig. 13H (200mg/kg
EthYL) shows intact and activated MCs with no sign of degranulation.
Fig. 13I (200mg/kg EthYL) on the other hand, shows intact, activated
and moderately degranulated MCs.
From the histological evaluation of the MCs made, the EthYL at all
doses, demonstrates a higher stabilizing activity than EthOL. And since
nerve endings reside in the dermal region and responds to granules
released by MCs during inflammatory conditions [41], this may partly
explain the relatively reduced nociceptive sensitisation and the high
anti-inflammatory activity as compared to the negative control groups.
Thus, from the histopathological results, the high dose (200mg/kg) of
the EthYL, showed the highest stabilizing effect of the connective tissue
MCs and demonstrated minimal perivascular PMNL infiltrate within its
tissue section.
4. Discussion
This study was conducted to ascertain the therapeutic usefulness of
young and old leaves of V. amygdalina in managing pain, edema, and
Fig. 9. Effect of pre-treatment of mice with (a) naloxone (2mg/kg i.p.), (b) atropine (5mg/kg, i.p.), (c) nifedipine (10mg/kg, p.o.), (d) glibenclamide (8mg/kg, p.o.)
(e) L- NAME (10mg/kg, i.p) and (f) yohimbine (3mg/kg, p.o.), on the anti-nociceptive profile of morphine (3mg/kg, i.p.) in phase 1 and phase 2 of formalin-induced
nociception. Each column represents the mean of 5 animals and the error bars indicate S.E.M.
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pyrexia associated with acute inflammation. Baker’s yeast was used to
induce experimental pyrexia, while carrageenan was used to induce
experimental edema and cold allodynia in Sprague-Dawley rats. Tail
immersion was also used to induce thermal hyperalgesia which in-
creased pain sensitivity [20]. Further assessment of pain was done using
the formalin-induced nociceptive model and possible mechanism of
action of the extracts evaluated.
In the current study, we compared the efficacy of EthYL and EthOL
as anti-inflammatory agent and analgesic using different pain models.
Intraplantar injection of carrageenan is known to induce the release of
inflammatory mediators such as prostaglandins and other cyclo-oxy-
genase (COX) products [43,44], Non-steroidal anti-inflammatory drugs
(NSAIDS) are known to mediate their pharmacological actions through
the inhibition of cyclo-oxygenase (COX) enzymes [45]. Both EthYL and
EthOL (200mg/kg) significantly inhibited the paw edema in the 4th
hour post- carrageenan induction. These results suggest that both EthYL
and EthOL extracts might act as peripheral analgesics, altering the local
reaction caused by the release of pain and inflammatory mediators.
We then examined the effect of these extracts using the cold allo-
dynia. In this test, hyperalgesia was induced by intraplantar injection
carrageenan into the rats’ right hind paw and the same paws were in-
serted into cold water (4 °C). Allodynia is a hallmark symptom of
neuropathic pain, which occurs when non innocuous stimuli stimulate
Aß-fibers or low-threshold Aδ- and C- nociceptive fibers [46,47]. Car-
rageenan pre-treatment is known to initiate an acute inflammatory
response which lowers pain threshold of nociceptors within the per-
iphery leading to central sensitization and hypersensitivity [48].
However, treatment with both EthYL and EthOL significantly inhibited
the cold allodynia.
Tail immersion test is another important acute pain model used to
screen for centrally acting analgesics and opioid receptor agonist.
Hyperalgesia measured in the tail immersion model involves supra-
spinal and spinal structures of the central nervous system (CNS) [49],
and is selective for compounds that act by the activation of opioid
Fig. 10. Effect of pre-treatment of mice
with naloxone (2mg/kg i.p.), atropine
(5mg/kg, i.p.), nifedipine (10mg/kg,
p.o.), glibenclamide (8mg/kg, p.o.), L-
NAME (10mg/kg, i.p), yohimbine
(3mg/kg, p.o.), on the anti-nociceptive
profile of (a) EthYL (200mg/kg, p.o.),
(b) EthOL (200mg/kg, p.o.) and (c)
morphine (3mg/kg, i.p.) in phase 1 and
phase 2 of formalin-induced nocicep-
tion. Each column represents the mean
of 5 animals and the error bars indicate
S.E.M. compared to respective vehicle-
treated controls; ***P < 0.001,**P<
0.01 and *P< 0.05 compared to ve-
hicle treated control and †††P< 0.001,
††P< 0.01 and †P< 0.05 compared
to either EthYL (200mg/kg, p.o.),
EthOL (200mg/kg, p.o.) or morphine
3mg/kg treated control (all one-way
ANOVA followed by Newman-Keuls’
post hoc).
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receptors. The posterior (dorsal) horn of the spinal cord is endowed
with several neurotransmitters and receptors, such as substance P,
neuropeptide Y, inhibitory amino acid, nitric oxide (NO), endogenous
opioids, bradykinin and monoamines, which are major targets for pain
medications [50]. Compounds that can inhibit thermal hyperalgesia
interact with κ-opioid receptors and produce analgesia by causing hy-
perpolarization of interneurons within the dorsal spinal cord and de-
pressing the release of transmitters such as enkephalin, serotonin, or
norepinephrine, and specific receptors located on the nociceptive fibers
that transmit pain sensation to the higher centers. Phytopharmaceu-
ticals can also interact with μ-opioid receptors located in the suprasp-
inal structures and activate the supraspinal system to release en-
dorphins that inhibit the transmission of pain signals by these fibers
[51,52]. In contrast, some non-steroidal anti-inflammatory drugs
(NSAIDs) such as Diclofenac act by inhibiting both peripheral and
central pain and is used as a reference drug in this study [53,54]. Both
EthYL and EthOL of VA increased the latency period while decreasing
thermal hyperalgesia, similar to Diclofenac.
Formalin test is also a highly predictive pain model which mimics
acute and clinical pain [47]. This model was used to assess the me-
chanism of action of the EthYL and EthOL extracts [37,38]. EthYL ex-
tracts produced a significantly higher anti-nociceptive effect in both
neurogenic and inflammatory phases compared to the EthOL at all dose
levels in a dose-dependent pattern. This agrees with the analgesic effect
observed in the tail immersion and cold allodynia models.
Further evaluation for the mechanism of analgesic effect was carried
out and observed results showed that, naloxone, a nonselective opioid
antagonist, significantly reversed the anti-nociceptive effect of both
EthYL and EthOL in both phases of the formalin-induced nociception;
suggesting a possible opioidergic involvement in their mechanisms of
actions. Also, a nitric oxide (NO) synthase inhibitor (L-NAME) sig-
nificantly reversed the anti-nociception produced by both extracts.
Nitric oxide is known to play a complex part in transmission of noci-
ceptive signals peripherally and centrally [55,56]. The anti-nociceptive
effect of EthYL and EthOL could possibly involve nitric oxide cyclic
GMP pathway. Additionally, atropine (nonselective muscarinic receptor
antagonist) significantly reversed the anti-nociceptive effect of EthYL,
but not EthOL. These results implicate the involvement of muscarinic
cholinergic system in the mechanism of action of EthYL.
In vitro studies have demonstrated the anti-inflammatory activity of
flavonoids by the inhibiting the synthesis of various pro-inflammatory
mediators such as eicosanoids, cytokines, adhesion molecules and C-
reactive protein [57]. Alkaloid [58], tannin [59], flavonoid [60] and
saponin fractions [61] have been reported to be responsible for the
analgesic ability of medicinal plants. The analgesic activity of saponins
and flavonoids have been identified via inhibition of the synthesis and
activities of enzymes involved in the production of inflammatory-re-
lated chemical mediators, such as prostaglandins [62], while alkaloids
inhibit pain via opioid receptors in the CNS [63]. Observed results
shows that EthYL has more potent anti-inflammatory and analgesic
Fig. 11. Photomicrograph of tissue section of the right hind-paw in formalin induced nociceptive test (H&E ×100). (A) Normal control: the dermis appears normal
(B) Negative control: the leukocyte infiltration is severe (blue arrowhead), dilation and congestion of vessels are evident (yellow arrowhead) (C) Positive control:
shows very mild levels of leukocytic infiltrate (blue arrowhead), accompanied by edema (yellow asterisks) (D) EthYL 50mg/kg: section depicts moderate leuko-
cytosis (blue arrow head) (E) EthOL 50mg/kg: leukocytosis (blue arrow head) and mild edema (yellow asterisks) present (F) EthYL 100mg/kg: mild edema present.
Tissue consistency is fairly normal (G) EthOL 100mg/kg: section shows mild leukocytosis (blue arrowhead) accompanied by congestion (yellow arrowhead) (H)
EthYL 200mg/kg: Tissue architecture comparable to the normal control (I) EthOL 200mg/kg: leukocytosis (blue arrowhead) is mild accompanied with mild edema
(yellow asterisk) (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article).
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activity, relative to the EthOL. Difference in the amount of the bioactive
compounds and antioxidant capacities may play a significant role in the
results realized.
Also, high levels of TAC are reported to protect tissues from injury
caused by oxidation reactions, reducing inflammation-induced pain
[64]. High levels of TAC was observed in YL, relative to OL, and similar
results were reported in a previous study [15]. This could be re-
sponsible for the anti-inflammatory activity of the YL by reducing the
oxidative stress induced by reactive oxygen species (ROS) during the
inflammatory process [65], and could be partly attributed to the an-
algesic activity of this group.
MCs are main effector cells of allergic and other inflammatory re-
actions [66,67]. They are predominantly found in the dermis near
blood vessels, nerves or the basement membrane of endothelial cells.
They possess cytoplasmic granules containing histamine, serotonin,
proteases and various cytokines including TNF, IL, fibroblast growth
factors (FGF), and epithelial growth factor (EGF), that mediates in-
flammation [68,69]. This implies that the inhibition of MC activity can
subsequently lead to inhibition of inflammation. Observed results from
histopathological analysis, showed severe MC degranulation in the
negative control accompanied by vasodilatation and high leukocytosis,
and lowest in both 100 and 200mg/kg of both EthYL and EthOL ex-
tracts. It was moderate in those treated with aspirin (positive control),
whiles 50mg/kg of both extracts showed significant MC degranulation.
Most importantly, EthYL at all doses (50–200mg/kg), showed de-
crease levels of MC degranulation as compared with their old coun-
terparts (50–200mg/kg EthYL). This could be due to the higher
antioxidant effect in EthYL as shown in the current results. This is in
accordance with previous research that demonstrated the antioxidant
stabilizing activity of drugs and extracts on MCs [41,70,71]. Taken
together, this suggest that, EthYL was able to reduce or inhibit the
transmigration and trafficking of pro-inflammatory cells such as neu-
trophils to site of formalin induction, partly by the stabilization of re-
sidential MCs in a more efficient manner, as compared to EthOL.
The subcutaneous injection of Saccharomyces cerevisae suspension
introduces exogenous pyrogens that induce the production of pro-in-
flammatory cytokines such as interleukins 1β and 6 (IL-1β, IL-6), in-
terferon (IF-α) and tumor necrosis factor (TNF) [8]. These cytokines
enter hypothalamic circulation and stimulate the release of local pros-
taglandins, mainly Prostaglandin E2 (PGE2) which elevate the hy-
pothalamic thermal set point beyond normal temperatures [72,73].
Phytochemical screening of VA revealed the presence of steroids,
tannins, triterpenoids, flavonoid, and glycosides [15], which have been
demonstrated to be responsible for the antipyretic abilities of many
medicinal plants [74–76], including VA [61,77]. Our results demon-
strate that both EthYL and EthOL extracts exhibit antipyretic activity.
However, a 2-fold increase in the anti-pyretic activity was observed in
the EthYL extracts, relative to the EthOL. This once more, could be
attributed to the difference in the amount of the bioactive compounds
and antioxidant prowess of the two extracts.
The cumulative effect of other unscreened novel bioactive com-
pounds present in the EthYL, acting in a synergistic fashion (other than
saponins only), may be partially responsible for the potent anti-in-
flammatory, analgesic and antipyretic activity of the EthYL realized in
Fig. 12. Photomicrograph of tissue section of the right hind paw in formalin induced nociceptive test (H&E ×400). It depicts immune cell infiltrates in association
with Mast cell (MC) degranulation dynamics. Neutrophilic/leucocytic immune infiltrate: Black arrowhead; Non-activated/intact MCs: Red arrowhead; Mild to
moderate degranulation: Yellow arrowhead; Severe degranulation: Green arrowhead. (A) Normal control: section shows intact MC devoid of neutrophilic infiltrates (B)
Negative control: severe degranulation of MCs, accompanied by high leucocytic infiltrate (C) Positive control: shows few moderately degranulated and intact MCs
with very mild leucocytosis (D) EthYL 50mg/kg: few neutrophilic infiltrate. (E) EthOL 50mg/kg: show moderate neutrophilic infiltrate. (F) EthYL 100mg/kg:
activated MC, with very few neutrophilic infiltrates (G) EthOL 100mg/kg: sections show moderate neutrophilic infiltrates. (H) EthYL 200mg/kg: section shows
intact or non-activated MC with very few neutrophilic infiltrate (I) EthOL 200mg/kg: both intact and moderately degranulated MCs, with moderate leucocytosis (For
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article).
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this study.
Thus, it will be interesting for further studies to be carried out to
unravel these bioactive compounds in EthYL.
5. Conclusion
Young and Old leaves of V. amygdalina ameliorate pyrexia, cold
allodynia, thermal hyperalgesia, and edema associated with acute in-
flammation. Both extracts ameliorated the neurogenic and in-
flammatory phases of the formalin induced nociception, with the EthYL
being slightly more potent than EthOL. The mechanism of action of
both EthYL and EthOL possibly involves the opioidergic and nitric oxide
cyclic GMP pathways. EthYL may have an additional mechanism which
implicates the muscarinic cholinergic system.
Indeed, the EthYL shows promise as a potent agent for conditions
associated with inflammation (pain, swelling and fever), and clearly
justifies the indigenous use of these young leaves for the treatment of
the aforementioned conditions in the southern part of Ghana.
Also, considering the days used by the young leaves to reach
5.10 cm (lower limit by length), plus the estimated 21 days, we propose
that VA leaves should be at most, 30 days old to be considered as young
vegetative leaves, for its usage as potent antipyretic, analgesic and anti-
inflammatory agents.
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Fig. 13. Photomicrograph of tissue section of the right hind paw in formalin induced nociceptive test (Toluidine blue ×400). It shows mast cell (MC) activation and
degranulation dynamics. Non-activated/intact MCs: Red arrowhead; Activated: Black arrowhead; Mild to moderate degranulation: Yellow arrowhead; Severe de-
granulation: Green arrowhead. (A) Normal control: section shows intact MC (B) Negative control: severe degranulation of MCs (C) Positive control: shows activated
and moderately degranulated MCs (D) EthYL 50mg/kg: mild degranulation in this group (E) EthOL 50mg/kg: sever to moderate degranulation. (F) EthYL 100mg/
kg: shows activated MCs (G) EthOL 100mg/kg: reveals mild degranulation (H) EthYL 200mg/kg: MCs in this section could be likened to the normal control (I) EthOL
200mg/kg: both intact, activated and moderately degranulated MCs (For interpretation of the references to colour in this figure legend, the reader is referred to the
web version of this article).
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